New York-based Axsome Therapeutics published results from the pivotal Phase III Gemini trial of AXS-05 (dextromethorphan-bupropion) in major depressive disorder (MDD).
https://www.pharmalive.com/wp-content/uploads/2022/06/Axsomes-Phase-III-results-show-significant-improvement-in-depression-BioSpace-6-1-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-06-01 12:03:412022-06-01 13:15:04Axsome’s Phase III Results Show Significant Improvement in Depression
